Back A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® Signs Strategic Agreement with Neptunus Biotechnology


Shanghai, China – On December 28, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") reached a strategic agreement with Shenzhen Neptunus Biotechnology Co, Ltd. ("Neptunus Biotechnology"). MicroPort® Chief Marketing Officer Bo Peng and Neptunus Biotechnology Chief Executive Officer Zhihong Wang signed the agreement on behalf of the two companies. Meanwhile, MicroPort® entered into a cooperation agreement with Neptunus Juying Medical Device Distribution Service Platform. Lei Jiang, MicroPort® First Vice President of Domestic Coronary Sales & Marketing, and Ling Luo, General Manager of Neptunus Juying Medical Technology (Shanghai) Co. Ltd., signed the distribution agreement on behalf of the two companies.
MicroPort® and Neptunus Biotechnology reached the strategic agreement in order to cope with new medical device policies, such as Two Invoice System and Whole Process Traceability System. The two parties will share resources to explore innovative business modes. This partnership will bring together MicroPort®'s existing product lines and Neptunus Biotechnology's logistic platform and IT facilities in building up a professional nation-wide supply pipeline centered in cardiovascular interventional products to offer high-quality service to distributors, hospitals, and patients.
Founded in 1989, Shenzhen Neptunus Group Co., Ltd. is an innovation-oriented giant group in China focusing primarily on pharmaceutical industry. Currently, it has sales revenue exceeding 33 billion yuan and over 30,000 employees. Neptunus Biotechnology, a subsidiary of Shenzhen Neptunus Group Co., Ltd, is a China-listed pharmaceutical company focused on independent R&D, pharmaceutical product manufacturing, and pharmaceutical distribution. It has industry leading technology innovation system, modern logistics center, and complete product distribution channels. Neptunus Juying Medical Technology (Shanghai) Co. Ltd., established by Neptunus Biotechnology and Juying Medical, is a medical device distribution service platform offering delivery service to hospitals and product logistics service.
MicroPort® Chief Marketing Officer Bo Peng said, "We hope MicroPort® and Neptunus Group can achieve a win-win partnership to better adapt to the new industry policies and the changing supply chain market of the domestic medical industry. By sharing resources and leveraging complementary advantages in logistics and service, I think this partnership will help promote the two companies' business development as well as the development of the whole medical device industry in China."

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to:

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2019 MicroPort Scientific Corporation

Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6953


[Prev]:MicroPort® EP Attends 2018 Dunhuang Cardiovascular Disease Forum to Display Columbus™
[Next]:MicroPort® Endovascular Hercules™ Series Products Gain Regulatory Approval in Colombia